Lyell Immunopharma, Inc.

Lyell is a clinical-stage biotechnology company that develops autologous chimeric antigen receptor T-cell therapies for cancer patients. The company focuses on hematologic malignancies and solid tumors, modifying patient immune cells to target cancerous tissues. Its lead product candidate is rondecabtagene autoleucel, a dual-targeting CD19 and CD20 cell therapy in clinical trials for large B-cell lymphoma. The company also develops LYL273, a cell therapy candidate targeting guanylyl cyclase C for patients with advanced metastatic colorectal cancer. Lyell's therapies target cancer patients with relapsed, refractory, or advanced malignancies.

The company conducts clinical trials across the United States, Canada, and Australia, with one pivotal trial enrolling patients at about twenty-five sites. Lyell operates a dedicated manufacturing facility called the LyFE Manufacturing Center to produce cell therapies for clinical trials. In addition, its global licensing rights for LYL273 cover worldwide territories excluding mainland China, Hong Kong, Macau, and Taiwan. The provided text does not state the location of the company's headquarters.

Summary of the business section of Lyell Immunopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.